GENMAB AS/ DK0010272202 /
2024-05-27 7:57:41 AM | Chg. -12.2000 | Volume | Bid9:58:00 PM | Ask9:58:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
259.0000EUR | -4.50% | - Turnover: - |
261.1000Bid Size: 22 | 263.0000Ask Size: 22 | 17.31 bill.EUR | - | - |
GlobeNewswire
04-30
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire
04-03
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
GlobeNewswire
2023-10-17
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
GlobeNewswire
2023-09-25
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or...
GlobeNewswire
2023-09-04
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improve...
GlobeNewswire
2021-11-09
BioNTech Announces Third Quarter 2021 Financial Results and Corporate Update
GlobeNewswire
2021-10-19
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
GlobeNewswire
2021-09-20
Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previous...
GlobeNewswire
2021-08-09
BioNTech Announces Second Quarter 2021 Financial Results and Corporate Update
GlobeNewswire
2021-07-21
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021